TRCT
NPCE icon

Tower Research Capital (TRC)’s Neuropace NPCE Stock Holding History

Tower Research Capital (TRC)’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.4K Sell
1,019
-1,496
-59% -$22.4K ﹤0.01% 3746
2025
Q4 		$38.8K Buy
2,515
+578
+30% +$7.73K ﹤0.01% 2619
2025
Q3 		$20K Sell
1,937
-770
-28% -$7.26K ﹤0.01% 3312
2025
Q2 		$30.2K Buy
2,707
+1,946
+256% +$24.3K ﹤0.01% 3395
2025
Q1 		$9.35K Sell
761
-379
-33% -$4.74K ﹤0.01% 3791
2024
Q4 		$12.8K Sell
1,140
-63
-5% -$548 ﹤0.01% 3587
2024
Q3 		$8.38K Sell
1,203
-3,208
-73% -$23.5K ﹤0.01% 3966
2024
Q2 		$33.3K Buy
4,411
+648
+17% +$6.54K ﹤0.01% 3405
2024
Q1 		$49.7K Buy
3,763
+3,511
+1,393% +$50.1K ﹤0.01% 2280
2023
Q4 		$2.6K Buy
+252
New +$2.01K ﹤0.01% 5191
2023
Q3 		– Sell
-90
Closed -$404 – 6143
2023
Q2 		$404 Sell
90
-694
-89% -$3.14K ﹤0.01% 5657
2023
Q1 		$4K Sell
784
-4,928
-86% -$18.9K ﹤0.01% 5095
2022
Q4 		$9K Buy
5,712
+752
+15% +$1.67K ﹤0.01% 4224
2022
Q3 		$19K Buy
+4,960
New +$23.9K ﹤0.01% 3978
2022
Q2 		– Sell
-1,632
Closed -$13K – 6382
2022
Q1 		$13K Buy
1,632
+506
+45% +$4.37K ﹤0.01% 3988
2021
Q4 		$11K Buy
1,126
+569
+102% +$7.39K ﹤0.01% 4435
2021
Q3 		$9K Sell
557
-786
-59% -$16.5K ﹤0.01% 4453
2021
Q2 		$32K Buy
+1,343
New +$31.2K ﹤0.01% 3426

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Tower Research Capital (TRC)'s NPCE Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Neuropace (NPCE) stake by 59% in Q1 2026, selling an estimated $22.4K and leaving 1,019 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3746.

Tower Research Capital (TRC) first reported a position in NPCE in Q2 2021 and has held it in 18 quarters since. The position peaked at $49.7K in Q1 2024. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Tower Research Capital (TRC) held 1,019 shares of Neuropace worth $13.4K as of Q1 2026.
  • Tower Research Capital (TRC) sold 1,496 Neuropace shares in Q1 2026, an estimated $22.4K.
  • Neuropace made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3746 holding.
  • Tower Research Capital (TRC) first reported a position in Neuropace in Q2 2021 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Neuropace position peaked at $49.7K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.